Yesterday FDA announced that Vemurafenib (Zelboraf, PLX4032, RG7204 or RO5185426), the inhibitor of B-RAF (an enzyme, serine/threonine protein kinase), was approved for the treatment of the late stage melanoma. B-RAF is the most frequently mutated kinase in the human cancers (Bollag et al., 2010 Nature) and in melanomas it is mutated in about 50% of the cases
No comments:
Post a Comment